What question did this study set out to answer?

This analysis aims to examine the approval and subsequent withdrawal of rofecoxib, focusing on public health implications.

Failing the Public Health — Rofecoxib, Merck, and the FDA

View Full Paper

Ask AI

Bookmark

This analysis aims to examine the approval and subsequent withdrawal of rofecoxib, focusing on public health implications.
Chronological review of events from approval to withdrawal of rofecoxib.
Analysis of communication and decision-making processes within Merck and the FDA.
Assessment of public health consequences stemming from the drug's usage.
Rofecoxib was withdrawn after over 80 million prescriptions due to increased risks of myocardial infarctions and strokes.
The withdrawal marks the largest prescription-drug withdrawal in history.
Warnings about rofecoxib's risks were largely ignored by both Merck and the FDA.

No takes yet. Share an insight, caveat, or question.

Analysis reveals the consequences of Rofecoxib's approval and withdrawal affecting public health.

Eric J. Topol (2004) studied this question.

View Full Paper

Ask AI

Bookmark